10 results on '"L, Criniere"'
Search Results
2. Prise en charge chirurgicale des strabismes compliquant une orbitopathie dysthyroïdienne : étude rétrospective monocentrique d’une série de 32 cas
- Author
-
P. Pierre, L. Criniere, Boris Laure, Sophie Arsene, M. Santallier, P.-J. Pisella, T. Pichard, and A Paillard
- Subjects
03 medical and health sciences ,Ophthalmology ,0302 clinical medicine ,030221 ophthalmology & optometry ,030209 endocrinology & metabolism - Abstract
Resume Introduction L’atteinte oculomotrice dans l’orbitopathie dysthyroidienne est a l’origine de troubles oculomoteurs restrictifs. Nous rapportons notre prise en charge chirurgicale chez ces patients. Patients et methodes Nous presentons une etude retrospective portant sur 32 patients operes entre 2008 et 2017. La chirurgie etait proposee en phase inactive avec troubles oculomoteurs stables depuis au moins 6 mois. Elle etait realisee sous anesthesie generale avec comme geste principal un recul des muscles restrictifs sans suture ajustable. Nous avons hierarchise les resultats postoperatoires en fonction, de la persistance ou non d’une diplopie en position primaire ou en position de lecture, et en fonction d’un recours ou non a une compensation prismatique. Resultats Trente-deux patients, dont 21 femmes et 11 hommes, d’âge moyen 53 ans ont ete inclus dans cette etude. Le recul moyen est de 9,6 mois. Huit patients avaient un trouble oculomoteur apparu suite a une decompression orbitaire. Quinze patients ont ete operes d’une chirurgie verticale, 8 d’une chirurgie horizontale et 9 d’une chirurgie mixte. Le nombre moyen de temps chirurgical est de 1,31 (1 a 3). A l’issue des differents temps operatoires, nous obtenons un resultat excellent chez 28 patients (87,5 %), bon chez 4 patients (12,5 %) et une amelioration statistiquement significative de la vision stereoscopique en postoperatoire (p Conclusion Cette technique chirurgicale avec sutures fixes, nous permet d’obtenir d’excellents resultats sur l’alignement oculaire et la disparition de la diplopie, avec un taux de reintervention comparable a d’autres techniques, telles que les sutures ajustables, ou la correction de la restriction musculaire.
- Published
- 2018
- Full Text
- View/download PDF
3. Case report from Tours Hospital. A 32-year-old woman with acquired Brown's syndrome associated with Hashimoto's thyroiditis
- Author
-
F. Domengie, N. Tarfaoui, L. Criniere, M. Santallier, R.K. Khanna, Sophie Arsene, and Pierre-Jean Pisella
- Subjects
Pediatrics ,medicine.medical_specialty ,Brown's syndrome ,business.industry ,MEDLINE ,030209 endocrinology & metabolism ,medicine.disease ,Thyroiditis ,03 medical and health sciences ,Ophthalmology ,0302 clinical medicine ,030221 ophthalmology & optometry ,medicine ,business - Published
- 2016
- Full Text
- View/download PDF
4. [Surgical management of strabismus in dysthyroid orbitopathy: A retrospective single-center study of 32 cases]
- Author
-
T, Pichard, A, Paillard, M, Santallier, L, Criniere, P, Pierre, P-J, Pisella, B, Laure, and S, Arsene
- Subjects
Adult ,Graves Ophthalmopathy ,Male ,Strabismus ,Postoperative Complications ,Humans ,Female ,Ophthalmologic Surgical Procedures ,Middle Aged ,Decompression, Surgical ,Aged ,Retrospective Studies - Abstract
Thyroid-related immune orbitopathy often results in a restrictive strabismus. We report our experience of surgical management in these cases.We present a retrospective case series conducted on 32 patients, operated between 2008 and 2017. Strabismus surgery was proposed in the postinflammatory stage with stable clinical findings for at least 6 months. It was performed under general anesthesia by recessions of restrictive muscles using a fixed suture technique. Outcomes were graded as excellent, good or poor, according to the presence or absence of diplopia in primary or reading positions, and according to whether prism prescription was necessary.The study included 32 patients (21 women, 11 men) with a mean age of 53 years. Average follow-up was 9.6 months. Eight patients developed diplopia after orbital decompression. Fifteen patients had vertical surgery, 8 horizontal surgery, 9 mixed surgery. A mean of 1.31 surgeries (range 1-3) were performed. After all surgeries, 28 patients (87.5 %) had an excellent outcome, 4 (12.5 %) had a good outcome, and none had a poor outcome. There was a significant improvement in stereoscopic acuity (P0.01), but not motility. Among the 8 patients who developed diplopia after orbital decompression, a clinically acceptable final outcome was achieved after only one surgery.Strabismus surgery using conventional non-adjustable sutures provides excellent ocular alignment and relief from diplopia in the majority of patients with dysthyroid strabismus. The reoperation rate is similar to other techniques, such adjustable suture and intraoperative relaxed muscle technique.
- Published
- 2017
5. Underdiagnosis of obstructive sleep apnoea syndrome in patients with type 2 diabetes in France: ENTRED 2007
- Author
-
P. Lecomte, Anne Fagot-Campagna, C. Druet, L. Criniere, and C. Fuhrman
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Population ,Excessive daytime sleepiness ,Comorbidity ,Type 2 diabetes ,Endocrinology ,Risk Factors ,Surveys and Questionnaires ,Epidemiology ,Prevalence ,Internal Medicine ,medicine ,Humans ,Mass Screening ,Obesity ,Sex Distribution ,education ,Aged ,Aged, 80 and over ,Sleep Apnea, Obstructive ,education.field_of_study ,business.industry ,Snoring ,General Medicine ,Middle Aged ,medicine.disease ,nervous system diseases ,respiratory tract diseases ,Cross-Sectional Studies ,Blood pressure ,Diabetes Mellitus, Type 2 ,Social Class ,Hypertension ,Quality of Life ,Breathing ,Educational Status ,Population study ,Female ,France ,medicine.symptom ,business - Abstract
Aim This study estimated the prevalence of symptoms evocative of obstructive sleep apneoa (OSA) in patients with type 2 diabetes and the proportion of those with evidence of a previous diagnosis or diagnostic procedure. Methods In ENTRED 2007, 8926 people reimbursed for at least three antidiabetic agents within the last 12 months were randomly selected, and 3894 answered a self-administered questionnaire. Symptoms evocative of OSA were defined as frequent snoring with excessive daytime sleepiness and/or witnessed sleep apneoa. Patients were considered to have evidence of a previous diagnostic procedure if they reported an OSA diagnosis or had a sleep recording done, or if a sleep recording was found in the hospital discharge or medical claims database, or if they were currently being treated with nocturnal ventilation. Results The patients' mean age was 66 years. Around 8.5% reported being diagnosed with OSA, 4.2% were treated with nocturnal ventilation and 16% had symptoms evocative of OSA. Being male, obesity, high blood pressure, insulin treatment, living with a partner, lower educational level and financial difficulties were all associated with symptoms suggestive of OSA. Overall, 13% had evidence of a previous diagnostic procedure, and the rate was 35% among those with symptoms evocative of OSA. Conclusion OSA is underdiagnosed in French diabetic patients, while the prevalence of symptoms is high. Only 13% of the study population and 35% of those with symptoms suggestive of OSA had benefited from a diagnostic procedure. It is of the utmost importance to better diagnose OSA in the diabetic population.
- Published
- 2013
- Full Text
- View/download PDF
6. Taux de rémission et de récidive dans une population de patients suivis pour une maladie de Cushing diagnostiquée entre 1990 et 2015 dans les six CHU du Grand-Ouest (Angers, Brest, Nantes, Poitiers, Rennes, Tours)
- Author
-
E. Sonnet, Claire Briet, P. Thuillier, Richard Marechaud, A. Louboutin, Delphine Drui, L. Criniere, A. Esvant, and Véronique Kerlan
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
Objectif La maladie de Cushing est une pathologie rare, responsable d’une morbi-mortalite elevee. La chirurgie hypophysaire ne garantit pas une remission complete et durable. Le but de l’etude est d’evaluer le taux de remission a 3 mois postoperatoire, le taux de recidive au cours du suivi et les facteurs peri-operatoires pronostiques. Materiel et Methodes Les patients majeurs presentant une maladie de Cushing diagnostiquee entre 1990 et 2015, recrutes par l’intermediaire des resultats anatomopathologiques des six CHU, ont ete inclus. Resultats Parmi les 176 patients inclus, 171 ont subi une chirurgie. Le taux de remission des patients a 3 mois postoperatoire etait de 78 %. La mediane de suivi etait de 5 ans. Le taux de recidive etait de 28 % avec un delai median de survenue d’une recidive de 3 ans. La taille des adenomes superieure a 10 mm, l’envahissement du sinus caverneux, l’exerese macroscopiquement incomplete et le cortisol plasmatique postoperatoire immediat non effondre etaient des facteurs de risque de non-remission. Le sexe masculin, le cortisol plasmatique postoperatoire immediat non effondre, le cortisol libre urinaire (CLU) et l’ACTH preoperatoire eleve etaient des facteurs de risque de survenue d’une recidive. Discussion Les taux de remission et de recidive ainsi que les facteurs de risque de non-remission degages par l’etude sont en accord avec les donnees de la litterature. A notre connaissance, le sexe masculin, le CLU et l’ACTH pre-operatoires eleves n’etaient pas decrits comme facteurs pronostiques d’une recidive.
- Published
- 2016
- Full Text
- View/download PDF
7. Hyperplasie thymique et anticorps antithyroglobuline élevés dans le suivi de cancer différencié de la thyroïde : y’a t’il un lien ?
- Author
-
P. Renoult-Pierre, L. Cloix, M. Santiago-Ribeiro, F. Borrelly, V. Arnault, Y. Venel, and L. Criniere
- Subjects
Radiological and Ultrasound Technology ,Biophysics ,Radiology, Nuclear Medicine and imaging - Abstract
Objectifs Les anticorps antithyroglobuline (AcTg) presents dans 20–40 % chez les patients avec un cancer bien differencie de la thyroide (CBDT) peuvent interferer avec la mesure de la thyroglobuline (Tg), marqueur essentiel de la surveillance, induisant des faux negatifs. Parmi les patients suivis pour CBDT avec un taux d’AcTg eleve, certains presentaient une hyperplasie thymique. L’objectif est de montrer un eventuel lien entre l’hyperplasie thymique et le taux eleve d’AcTg afin d’ameliorer la surveillance dans cette population. Patients et methodes Analyse retrospective de 5 patients traites pour un CBDT ayant beneficie d’un dosage de TSH, T3, T4, Tg et AcTg sous stimulation thyreotrope et d’une echographie cervicale avant totalisation isotopique par 100 mCi d’iode 131. A j3, une scintigraphie corps entier ± tomographie couplee au TDM a ete realisee afin de detecter d’eventuelles masses tumorales residuelles. Le suivi a ete realise conformement aux consensus actuels. Dans le suivi, les patients ayant une suspicion de recidive clinique, biologique ou echographique ont beneficie d’une imagerie complementaire par scintigraphie a l’I131, TDM ou 18FDG TEP/TDM ayant permis la decouverte d’hyperplasie thymique. Resultats Cinq patients (3 F et 2 H) avaient des AcTg eleves (superieurs a trois fois la normale) et une hyperplasie thymique. Morphologiquement, 3/5 patients avaient un bilan d’imagerie negatif ou stable dans le temps. Deux sur cinq patients ont eu une recidive ganglionnaire initiale prouvee histologiquement et etaient stables sur le bilan d’imagerie apres chirurgie. Conclusions Un taux eleve d’AcTg chez des patients suivis pour CBDT presentant une hyperplasie thymique a ete constate. L’hypothese, non decrite dans la litterature a ce jour, est qu’il pourrait exister un lien potentiel entre un « hyperfonctionnement » thymique avec production d’AcTg independamment de toute maladie tumorale sous-jacente. Une surveillance adaptee pourrait ainsi etre envisagee devant un taux d’anticorps eleve, mais stable dans le temps.
- Published
- 2015
- Full Text
- View/download PDF
8. Hyperthyroïdie paranéoplasique d’une mole hydatiforme
- Author
-
L. Cloix, P. Renoult-Pierre, B. Lioger, M. Monseu, and L. Criniere
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Published
- 2013
- Full Text
- View/download PDF
9. Hypoglycémies et tumeur fibreuse solitaire
- Author
-
P. Rosset, P. Lecomte, L. Criniere, C. Linassier, and Peggy Pierre
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Published
- 2012
- Full Text
- View/download PDF
10. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
- Author
-
Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, and Schlumberger M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Carcinoma, Neuroendocrine mortality, Carcinoma, Neuroendocrine pathology, Child, Female, France, Humans, Male, Middle Aged, Piperidines adverse effects, Protein Kinase Inhibitors adverse effects, Quinazolines adverse effects, Retrospective Studies, Risk Factors, Thyroid Neoplasms mortality, Thyroid Neoplasms pathology, Time Factors, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Carcinoma, Neuroendocrine drug therapy, Piperidines therapeutic use, Protein Kinase Inhibitors therapeutic use, Quinazolines therapeutic use, Thyroid Neoplasms drug therapy
- Abstract
Background: A randomized phase III trial demonstrated that vandetanib treatment is effective in patients with metastatic medullary thyroid cancer (MTC), leading to regulatory approval, but its use may be associated with toxicities that require specific monitoring and management. The objective of the present study performed in France was to describe the toxicity profile and efficacy of vandetanib treatment when given outside any trial., Methods: Sixty-eight patients were treated with vandetanib in the frame of a temporary use authorization (ATU) in France from August 2010 to February 2012, when the drug was available on request for patients with locally advanced or metastatic MTC. Patients were registered by the French health authorities, and characteristics, treatment parameters, toxicity profile, and efficacy were retrospectively reviewed. Eight patients were excluded from the analysis because vandetanib treatment was not administered (n=3), had been given in a trial before ATU (n=3), or was given for a non-MTC cancer (n=2)., Results: Data from the 60 MTC patients were analyzed. Mean age was 58 years (range 11-83 years), 39 patients were male, and six had hereditary MTC. Fifty-six (93%) had metastatic disease in the mediastinum (82%), bones (65%), liver (53%), or lung (53%), and four had only locally advanced disease. At the time of study evaluation, with a median follow-up of 20 months and a median duration of treatment of 9.7 months (range 0.3-36 months), 15 patients were continuing vandetanib treatment (range 18-36 months). Median progression-free survival was 16.1 months. Twenty-five patients discontinued treatment for disease progression (range 0.3-29 months). Best tumor response was a complete response in one patient, a partial response in 12 (20%), stable disease in 33 (55%), and progression in seven patients (12%). All patients had at least one adverse event (AE) during treatment. The main AEs were skin toxicity, diarrhea, and asthenia. Sixteen patients (27%) discontinued treatment for toxicity, and one patient died from vandetanib-induced cardiac toxicity., Conclusions: Vandetanib is an effective option for patients with advanced MTC. AEs should be monitored carefully and should be minimized by educating both patients and care providers and by applying symptomatic treatment and dose reduction.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.